{"DataElement":{"publicId":"6680644","version":"1","preferredName":"Testicular Cancer AJCC Edition 8 Group Stage","preferredDefinition":"Stage group based on the combination of T, N, and M categories and relevant prognostic factors for testicular carcinoma, using AJCC Ed. 8 criteria.","longName":"TESR_AJC8_DZ_STG","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"5644541","version":"1","preferredName":"Malignant Testicular Germ Cell Tumor Stage Grouping","preferredDefinition":"A malignant tumor predominantly affecting young men and often associated with cryptorchidism.  Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.","longName":"2986052v1.0:2230143v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2986052","version":"1","preferredName":"Malignant Testicular Germ Cell Tumor","preferredDefinition":"A malignant tumor predominantly affecting young men and often associated with cryptorchidism.  Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor. -- 2004","longName":"C9063","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Testicular Germ Cell Tumor","conceptCode":"C9063","definition":"A malignant germ cell tumor that arises from the testis. It predominantly affects young men. Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D112249-82D8-E0FD-E040-BB89AD432FCB","latestVersionIndicator":"Yes","beginDate":"2010-01-13","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-01-13","modifiedBy":"ONEDATA","dateModified":"2010-01-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2230143","version":"1","preferredName":"Stage Grouping","preferredDefinition":"Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F752037A-4CC2-36A8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-18","modifiedBy":"ONEDATA","dateModified":"2005-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Application","id":"47667353-FAF7-6F63-E053-F662850A2962","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"COOPERM","dateModified":"2017-01-31","changeDescription":"Created for CRF standard harmonization. mc 1/31/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6680575","version":"1","preferredName":"Testicular Carcinoma American Joint Committee on Cancer Edition 8 Group Stage","preferredDefinition":"A term that refers to the staging of testicular cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to postpubertal germ cell tumors of the testis and malignant sex cord-stromal tumors of the testis. It does not apply to spermatocytic tumors (no AJCC staging system), nonmalignant sex cord-/gonadal -stromal tumors (no AJCC staging system), prepubertal germ cell tumors (no AJCC staging system), hematolymphoid tumors (hematologic malignancies staging system), and paratesticular neoplasms (no AJCC staging system).  (from AJCC 8th Ed.)_An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"6680575v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"II","valueDescription":"Stage II Testicular Cancer AJCC v8","ValueMeaning":{"publicId":"6680577","version":"1","preferredName":"Stage II Testicular Cancer AJCC v8","longName":"6680577","preferredDefinition":"Stage II includes: Any pT/TX, N1-3, M0, SX. TX: Testicular cancer in which the primary tumor cannot be assessed. N1: Testicular cancer with metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension. N2: Testicular cancer with metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor. N3: Testicular cancer with metastasis with a lymph node mass larger than 5 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. SX: Marker studies not available or not performed. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage II Testicular Cancer AJCC v8","conceptCode":"C140233","definition":"Stage II includes: Any pT/TX, N1-3, M0, SX. TX: Testicular cancer in which the primary tumor cannot be assessed. N1: Testicular cancer with metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension. N2: Testicular cancer with metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor. N3: Testicular cancer with metastasis with a lymph node mass larger than 5 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. SX: Marker studies not available or not performed. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84AF930E-B6E0-0529-E053-F662850A6044","latestVersionIndicator":"Yes","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"84AF930E-B6F9-0529-E053-F662850A6044","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","deletedIndicator":"No"},{"value":"IS","valueDescription":"Stage IS Testicular Cancer AJCC v8","ValueMeaning":{"publicId":"6680579","version":"1","preferredName":"Stage IS Testicular Cancer AJCC v8","longName":"6680579","preferredDefinition":"Stage IS includes: Any pT/TX, N0, M0, S1-3. TX: Testicular cancer in which the primary tumor cannot be assessed. N0: Testicular cancer with no regional lymph node metastasis. M0: Testicular cancer without evidence of distant metastasis. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. S2: LDH 1.5-10 x N or hCG (mlU/mL) 5,000-50,000 or AFP (ng/mL) 1,000-10,000. S3: LDH more than 10 x N or hCG (mlU/mL) more than 50,000 or AFP (ng/mL) more than 10,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IS Testicular Cancer AJCC v8","conceptCode":"C140232","definition":"Stage IS includes: Any pT/TX, N0, M0, S1-3. TX: Testicular cancer in which the primary tumor cannot be assessed. N0: Testicular cancer with no regional lymph node metastasis. M0: Testicular cancer without evidence of distant metastasis. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. S2: LDH 1.5-10 x N or hCG (mlU/mL) 5,000-50,000 or AFP (ng/mL) 1,000-10,000. S3: LDH more than 10 x N or hCG (mlU/mL) more than 50,000 or AFP (ng/mL) more than 10,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84AF930E-B706-0529-E053-F662850A6044","latestVersionIndicator":"Yes","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"84AF930E-B71F-0529-E053-F662850A6044","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","deletedIndicator":"No"},{"value":"IIIC","valueDescription":"Stage IIIC Testicular Cancer AJCC v8","ValueMeaning":{"publicId":"6680581","version":"1","preferredName":"Stage IIIC Testicular Cancer AJCC v8","longName":"6680581","preferredDefinition":"Stage IIIC includes: (Any pT/TX, N1-3, M0, S3); (Any pT/TX, Any N, M1a, S3); (Any pT/TX, Any N, M1b, Any S). TX: Testicular cancer in which the primary tumor cannot be assessed. N1: Testicular cancer with metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension. N2: Testicular cancer with metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor. N3: Testicular cancer with metastasis with a lymph node mass larger than 5 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. M1a: Testicular cancer with non-retroperitoneal nodal or pulmonary metastases. M1b: Testicular cancer with non-pulmonary visceral metastases. S3: LDH more than 10 x N or hCG (mlU/mL) more than 50,000 or AFP (ng/mL) more than 10,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIC Testicular Cancer AJCC v8","conceptCode":"C140240","definition":"Stage IIIC includes: (Any pT/TX, N1-3, M0, S3); (Any pT/TX, Any N, M1a, S3); (Any pT/TX, Any N, M1b, Any S). TX: Testicular cancer in which the primary tumor cannot be assessed. N1: Testicular cancer with metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension. N2: Testicular cancer with metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor. N3: Testicular cancer with metastasis with a lymph node mass larger than 5 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. M1a: Testicular cancer with non-retroperitoneal nodal or pulmonary metastases. M1b: Testicular cancer with non-pulmonary visceral metastases. S3: LDH more than 10 x N or hCG (mlU/mL) more than 50,000 or AFP (ng/mL) more than 10,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84AF930E-B72C-0529-E053-F662850A6044","latestVersionIndicator":"Yes","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"84AF930E-B745-0529-E053-F662850A6044","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","deletedIndicator":"No"},{"value":"IIC","valueDescription":"Stage IIC Testicular Cancer AJCC v8","ValueMeaning":{"publicId":"6680583","version":"1","preferredName":"Stage IIC Testicular Cancer AJCC v8","longName":"6680583","preferredDefinition":"Stage IIC includes: (Any pT/TX, N3, M0, S0); (Any pT/TX, N3, M0, S1). TX: Testicular cancer in which the primary tumor cannot be assessed. N3: Testicular cancer with metastasis with a lymph node mass larger than 5 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIC Testicular Cancer AJCC v8","conceptCode":"C140236","definition":"Stage IIC includes: (Any pT/TX, N3, M0, S0); (Any pT/TX, N3, M0, S1). TX: Testicular cancer in which the primary tumor cannot be assessed. N3: Testicular cancer with metastasis with a lymph node mass larger than 5 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84AF930E-B752-0529-E053-F662850A6044","latestVersionIndicator":"Yes","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"84AF930E-B76B-0529-E053-F662850A6044","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","deletedIndicator":"No"},{"value":"III","valueDescription":"Stage III Testicular Cancer AJCC v8","ValueMeaning":{"publicId":"6680585","version":"1","preferredName":"Stage III Testicular Cancer AJCC v8","longName":"6680585","preferredDefinition":"Stage III includes: Any pT/TX, Any N, M1, SX. TX: Testicular cancer in which the primary tumor cannot be assessed. M1: Testicular cancer with distant metastasis. SX: Marker studies not available or not performed. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage III Testicular Cancer AJCC v8","conceptCode":"C140237","definition":"Stage III includes: Any pT/TX, Any N, M1, SX. TX: Testicular cancer in which the primary tumor cannot be assessed. M1: Testicular cancer with distant metastasis. SX: Marker studies not available or not performed. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84AF930E-B778-0529-E053-F662850A6044","latestVersionIndicator":"Yes","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"84AF930E-B791-0529-E053-F662850A6044","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","deletedIndicator":"No"},{"value":"IIIB","valueDescription":"Stage IIIB Testicular Cancer AJCC v8","ValueMeaning":{"publicId":"6680587","version":"1","preferredName":"Stage IIIB Testicular Cancer AJCC v8","longName":"6680587","preferredDefinition":"Stage IIIB includes: (Any pT/TX, N1-3, M0, S2); (Any pT/TX, Any N, M1a, S2). TX: Testicular cancer in which the primary tumor cannot be assessed. N1: Testicular cancer with metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension. N2: Testicular cancer with metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor. N3: Testicular cancer with metastasis with a lymph node mass larger than 5 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. M1a: Testicular cancer with non-retroperitoneal nodal or pulmonary metastases. S2: LDH 1.5-10 x N or hCG (mlU/mL) 5,000-50,000 or AFP (ng/mL) 1,000-10,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIB Testicular Cancer AJCC v8","conceptCode":"C140239","definition":"Stage IIIB includes: (Any pT/TX, N1-3, M0, S2); (Any pT/TX, Any N, M1a, S2). TX: Testicular cancer in which the primary tumor cannot be assessed. N1: Testicular cancer with metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension. N2: Testicular cancer with metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor. N3: Testicular cancer with metastasis with a lymph node mass larger than 5 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. M1a: Testicular cancer with non-retroperitoneal nodal or pulmonary metastases. S2: LDH 1.5-10 x N or hCG (mlU/mL) 5,000-50,000 or AFP (ng/mL) 1,000-10,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84AF930E-B79E-0529-E053-F662850A6044","latestVersionIndicator":"Yes","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"84AF930E-B7B7-0529-E053-F662850A6044","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","deletedIndicator":"No"},{"value":"IIB","valueDescription":"Stage IIB Testicular Cancer AJCC v8","ValueMeaning":{"publicId":"6680589","version":"1","preferredName":"Stage IIB Testicular Cancer AJCC v8","longName":"6680589","preferredDefinition":"Stage IIB includes: (Any pT/TX, N2, M0, S0); (Any pT/TX, N2, M0, S1). TX: Testicular cancer in which the primary tumor cannot be assessed. N2: Testicular cancer with metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIB Testicular Cancer AJCC v8","conceptCode":"C140235","definition":"Stage IIB includes: (Any pT/TX, N2, M0, S0); (Any pT/TX, N2, M0, S1). TX: Testicular cancer in which the primary tumor cannot be assessed. N2: Testicular cancer with metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84AF930E-B7C4-0529-E053-F662850A6044","latestVersionIndicator":"Yes","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"84AF930E-B7DD-0529-E053-F662850A6044","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","deletedIndicator":"No"},{"value":"IB","valueDescription":"Stage IB Testicular Cancer AJCC v8","ValueMeaning":{"publicId":"6680591","version":"1","preferredName":"Stage IB Testicular Cancer AJCC v8","longName":"6680591","preferredDefinition":"Stage IB includes: (pT2, N0, M0, S0); (pT3, N0, M0, S0); (pT4, N0, M0, S0). pT2: Testicular cancer which is limited to testis (including rete testis invasion) with lymphovascular invasion or invades hilar soft tissue or epididymis or penetrates visceral mesothelial layer covering the external surface of tunica albuginea with or without lymphovascular invasion. pT3: Testicular cancer in which the tumor invades spermatic cord with or without lymphovascular invasion. pT4: Testicular cancer in which the tumor invades scrotum with or without lymphovascular invasion. N0: Testicular cancer with no regional lymph node metastasis. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IB Testicular Cancer AJCC v8","conceptCode":"C140229","definition":"Stage IB includes: (pT2, N0, M0, S0); (pT3, N0, M0, S0); (pT4, N0, M0, S0). pT2: Testicular cancer which is limited to testis (including rete testis invasion) with lymphovascular invasion or invades hilar soft tissue or epididymis or penetrates visceral mesothelial layer covering the external surface of tunica albuginea with or without lymphovascular invasion. pT3: Testicular cancer in which the tumor invades spermatic cord with or without lymphovascular invasion. pT4: Testicular cancer in which the tumor invades scrotum with or without lymphovascular invasion. N0: Testicular cancer with no regional lymph node metastasis. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84AF930E-B7EA-0529-E053-F662850A6044","latestVersionIndicator":"Yes","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"84AF930E-B803-0529-E053-F662850A6044","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","deletedIndicator":"No"},{"value":"IIIA","valueDescription":"Stage IIIA Testicular Cancer AJCC v8","ValueMeaning":{"publicId":"6680593","version":"1","preferredName":"Stage IIIA Testicular Cancer AJCC v8","longName":"6680593","preferredDefinition":"Stage IIIA includes: (Any pT/TX, Any N, M1a, S0); (Any pT/TX, Any N, M1a, S1). TX: Testicular cancer in which the primary tumor cannot be assessed. M1a: Testicular cancer with non-retroperitoneal nodal or pulmonary metastases. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIA Testicular Cancer AJCC v8","conceptCode":"C140238","definition":"Stage IIIA includes: (Any pT/TX, Any N, M1a, S0); (Any pT/TX, Any N, M1a, S1). TX: Testicular cancer in which the primary tumor cannot be assessed. M1a: Testicular cancer with non-retroperitoneal nodal or pulmonary metastases. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84AF930E-B810-0529-E053-F662850A6044","latestVersionIndicator":"Yes","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"84AF930E-B829-0529-E053-F662850A6044","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","deletedIndicator":"No"},{"value":"IIA","valueDescription":"Stage IIA Testicular Cancer AJCC v8","ValueMeaning":{"publicId":"6680595","version":"1","preferredName":"Stage IIA Testicular Cancer AJCC v8","longName":"6680595","preferredDefinition":"Stage IIA includes: (Any pT/TX, N1, M0, S0); (Any pT/TX, N1, M0, S1). TX: Testicular cancer in which the primary tumor cannot be assessed. N1: Testicular cancer with metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIA Testicular Cancer AJCC v8","conceptCode":"C140234","definition":"Stage IIA includes: (Any pT/TX, N1, M0, S0); (Any pT/TX, N1, M0, S1). TX: Testicular cancer in which the primary tumor cannot be assessed. N1: Testicular cancer with metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84AF930E-B836-0529-E053-F662850A6044","latestVersionIndicator":"Yes","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"84AF930E-B84F-0529-E053-F662850A6044","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","deletedIndicator":"No"},{"value":"IA","valueDescription":"Stage IA Testicular Cancer AJCC v8","ValueMeaning":{"publicId":"6680597","version":"1","preferredName":"Stage IA Testicular Cancer AJCC v8","longName":"6680597","preferredDefinition":"Stage IA includes: pT1, N0, M0, S0. pT1: Testicular cancer which is limited to testis (including rete testis invasion) without lymphovascular invasion. N0: Testicular cancer with no regional lymph node metastasis. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IA Testicular Cancer AJCC v8","conceptCode":"C140228","definition":"Stage IA includes: pT1, N0, M0, S0. pT1: Testicular cancer which is limited to testis (including rete testis invasion) without lymphovascular invasion. N0: Testicular cancer with no regional lymph node metastasis. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84AF930E-B85C-0529-E053-F662850A6044","latestVersionIndicator":"Yes","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"84AF930E-B875-0529-E053-F662850A6044","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","deletedIndicator":"No"},{"value":"I","valueDescription":"Stage I Testicular Cancer AJCC v8","ValueMeaning":{"publicId":"6680599","version":"1","preferredName":"Stage I Testicular Cancer AJCC v8","longName":"6680599","preferredDefinition":"Stage I includes: pT1-T4, N0, M0, SX. pT1: Testicular cancer which is limited to testis (including rete testis invasion) without lymphovascular invasion. pT2: Testicular cancer which is limited to testis (including rete testis invasion) with lymphovascular invasion or invades hilar soft tissue or epididymis or penetrates visceral mesothelial layer covering the external surface of tunica albuginea with or without lymphovascular invasion. pT3: Testicular cancer in which the tumor invades spermatic cord with or without lymphovascular invasion. pT4: Testicular cancer in which the tumor invades scrotum with or without lymphovascular invasion. N0: Testicular cancer with no regional lymph node metastasis. M0: Testicular cancer without evidence of distant metastasis. SX: Marker studies not available or not performed. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage I Testicular Cancer AJCC v8","conceptCode":"C140227","definition":"Stage I includes: pT1-T4, N0, M0, SX. pT1: Testicular cancer which is limited to testis (including rete testis invasion) without lymphovascular invasion. pT2: Testicular cancer which is limited to testis (including rete testis invasion) with lymphovascular invasion or invades hilar soft tissue or epididymis or penetrates visceral mesothelial layer covering the external surface of tunica albuginea with or without lymphovascular invasion. pT3: Testicular cancer in which the tumor invades spermatic cord with or without lymphovascular invasion. pT4: Testicular cancer in which the tumor invades scrotum with or without lymphovascular invasion. N0: Testicular cancer with no regional lymph node metastasis. M0: Testicular cancer without evidence of distant metastasis. SX: Marker studies not available or not performed. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84AF930E-B882-0529-E053-F662850A6044","latestVersionIndicator":"Yes","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"84AF930E-B89B-0529-E053-F662850A6044","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","deletedIndicator":"No"},{"value":"0","valueDescription":"Stage 0 Testicular Cancer AJCC v8","ValueMeaning":{"publicId":"6680601","version":"1","preferredName":"Stage 0 Testicular Cancer AJCC v8","longName":"6680601","preferredDefinition":"Stage 0 includes: pTis, N0, M0, S0. pTis: Testicular cancer with a finding of germ cell neoplasia in situ. N0: Testicular cancer with no regional lymph node metastasis. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Testicular Cancer AJCC v8","conceptCode":"C140226","definition":"Stage 0 includes: pTis, N0, M0, S0. pTis: Testicular cancer with a finding of germ cell neoplasia in situ. N0: Testicular cancer with no regional lymph node metastasis. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84AF930E-B8A8-0529-E053-F662850A6044","latestVersionIndicator":"Yes","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"84AF930E-B8C1-0529-E053-F662850A6044","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6680574","version":"1","preferredName":"Testicular Cancer by AJCC v8 Stage Stage Grouping Stage","preferredDefinition":"A term that refers to the staging of testicular cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to postpubertal germ cell tumors of the testis and malignant sex cord-stromal tumors of the testis. It does not apply to spermatocytic tumors (no AJCC staging system), nonmalignant sex cord-/gonadal -stromal tumors (no AJCC staging system), prepubertal germ cell tumors (no AJCC staging system), hematolymphoid tumors (hematologic malignancies staging system), and paratesticular neoplasms (no AJCC staging system).  (from AJCC 8th Ed.):An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"C140225:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Testicular Cancer by AJCC v8 Stage","conceptCode":"C140225","definition":"A term that refers to the staging of testicular cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to postpubertal germ cell tumors of the testis and malignant sex cord-stromal tumors of the testis. It does not apply to spermatocytic tumors (no AJCC staging system), nonmalignant sex cord-/gonadal -stromal tumors (no AJCC staging system), prepubertal germ cell tumors (no AJCC staging system), hematolymphoid tumors (hematologic malignancies staging system), and paratesticular neoplasms (no AJCC staging system).  (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84AF930E-B6B3-0529-E053-F662850A6044","latestVersionIndicator":"Yes","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"ONEDATA","dateModified":"2019-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"84AF930E-B6C4-0529-E053-F662850A6044","latestVersionIndicator":"Yes","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"TAYLORT","dateModified":"2022-02-24","changeDescription":"TL released; 2/24/22. 3/22/19 created for standardization; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"10000296","version":"1","longName":"Testicular","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Disease stage","type":"Preferred Question Text","description":"Disease stage","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"84AF2221-E33C-107F-E053-F662850A5305","latestVersionIndicator":"Yes","beginDate":"2019-03-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-22","modifiedBy":"TAYLORT","dateModified":"2022-02-24","changeDescription":"TL released; 2/24/22.; 3/22/19 created for standardization; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}